Understanding genetic factors behind immune-related side effects of cancer treatments
Official title: Assessment of germline variants associated with immune-related adverse events following immune checkpoint inhibitors
Funded at Dana-Farber Cancer Inst · NIH-10942344 · Data updated 2026-11-12
This study is looking at how certain genes might affect the side effects that cancer patients experience when they receive immune therapy, with the hope of making these treatments safer and more effective for everyone.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | September 17, 2024 |
| Project end | August 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $689,934 |
| NIH project number | 1R01CA293091-01 |
| Project ID | NIH-10942344 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include cancer patients who are receiving or have received immune checkpoint inhibitors and may be at risk for immune-related adverse events.
✕Less likely to help
Patients who are not undergoing treatment with immune checkpoint inhibitors or those with conditions unrelated to cancer may not benefit from this research.
What this research studies
This research investigates the genetic variants that may contribute to immune-related adverse events (irAEs) experienced by patients undergoing treatment with immune checkpoint inhibitors (ICIs) for cancer. By analyzing data from over 13,000 patients, the study aims to identify specific genetic markers that can predict the likelihood and severity of these side effects. The goal is to enhance the safety and effectiveness of immunotherapy by distinguishing between beneficial immune responses and harmful side effects. This comprehensive approach combines genetic analysis with clinical data to improve patient outcomes.
Why it matters
Potential benefit: If successful, this research could lead to personalized treatment plans that minimize adverse effects while maximizing the effectiveness of cancer immunotherapy.
How similar studies have gone: Previous research has shown promising results in identifying genetic factors associated with immune-related adverse events, indicating that this approach has potential for success.
Where this research is happening
-
Dana-Farber Cancer Inst
Boston, United States Active
Researchers
- Principal investigator: Choueiri, Toni — Dana-Farber Cancer Inst
- Study coordinator: Choueiri, Toni
Related research
Other NIH-funded projects on the same topics.
-
Understanding how immune checkpoint drugs can trigger inflammatory arthritis in cancer patients
This research looks at why some cancer patients develop inflammatory arthritis after PD-1 inhibitor therapy and what could be done to prevent it.
-
Gut bacteria that can make cancer immunotherapy less effective
This project will see if reducing chronic inflammation driven by certain gut bacteria can help immunotherapy work better for people whose cancers have stopped responding.
-
Decoding how NSCLC patients respond and react to immunotherapy through noninvasive blood tests and tumor samples
A study in people with non-small cell lung cancer will look at blood and tumor samples to understand why some patients benefit from immunotherapy and who might have serious side effects.
-
Understanding skin reactions from immune cancer drugs and how our body’s immune system reacts to them
This grant explores why some people develop severe skin reactions when treated with immune checkpoint inhibitors and aims to use patient data and tissue studies to improve care.
-
Targeting NNMT in the tumor environment to make immunotherapy work better
Aiming to boost cancer treatment by blocking NNMT in the tumor’s supportive tissue so immune therapies work more effectively.
-
Using JAK inhibitors to calm autoimmune damage from cancer immunotherapy
A multi-center, early-phase trial will test whether a JAK inhibitor can help people who develop diabetes caused by cancer immunotherapy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.